Get the Stockscreener App
59.36
1.75%
1.02
After Hours:
59.45
0.09
+0.15%
Exact Sciences Corp stock is traded at $59.36, with a volume of 2.12M.
It is up +1.75% in the last 24 hours and up +10.05% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$58.34
Open:
$58.2
24h Volume:
2.12M
Relative Volume:
0.74
Market Cap:
$11.24B
Revenue:
$2.83B
Net Income/Loss:
$-1.02B
P/E Ratio:
-10.77
EPS:
-5.51
Net Cash Flow:
$194.14M
1W Performance:
+3.00%
1M Performance:
+10.05%
6M Performance:
+33.54%
1Y Performance:
-16.35%
1-Day Range:
$57.75
$59.69
1-Week Range:
$57.12
$60.26
52-Week Range:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
59.36 | 11.04B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Is Exact Sciences Corporation stock a buy in volatile markets2025 Buyback Activity & Expert Approved Trade Ideas - newser.com
How high can Exact Sciences Corporation stock goRate Hike & High Yield Equity Trading Tips - newser.com
Published on: 2025-10-12 23:07:32 - newser.com
EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
What’s the recovery path for long term holders of Exact Sciences CorporationNew Guidance & Safe Entry Trade Reports - newser.com
Exact Sciences Corporation $EXAS Shares Sold by Blair William & Co. IL - MarketBeat
Doyle, Exact Sciences director, sells $120k in shares By Investing.com - Investing.com Australia
Herriott James, Exact Sciences SVP, sells $90k in EXAS stock - Investing.com Canada
Insider Sell: James Doyle Sells 2,000 Shares of Exact Sciences C - GuruFocus
Doyle, Exact Sciences director, sells $120k in shares - Investing.com India
Can Exact Sciences Corporation (EXK) stock sustain institutional flowsJuly 2025 Final Week & Daily Profit Focused Stock Screening - newser.com
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock - Yahoo Finance
What analysts say about Exact Sciences Corporation EXK stockFibonacci Extensions & Free Unmatched Market Gains - earlytimes.in
Exact Sciences (EXAS): Taking Stock of Valuation Following Recent Share Price Momentum - Yahoo Finance
Piper Sandler raises Exact Sciences stock price target to $70 on Cologuard growth - Investing.com India
EXAS: Piper Sandler Raises Price Target to $70, Maintains Overwe - GuruFocus
Exact Sciences Corp.New Study in Journal of the National Cancer Institute Finds Cologuard Plus Provides the Most Life-Years Gained with the Fewest Colonoscopies - MarketScreener
Exact Sciences (NASDAQ:EXAS) Upgraded at Zacks Research - MarketBeat
Exact Sciences Corporation $EXAS Shares Bought by Gagnon Securities LLC - MarketBeat
Press Release: Exact Sciences Schedules Third Quarter 2025 Earnings Call - 富途牛牛
Exact Sciences Schedules Third Quarter 2025 Earnings Call - Business Wire
Exact Sciences Corporation $EXAS Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Evercore ISI Group Raises Price Target for EXAS to $68.00 | EXAS Stock News - GuruFocus
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar - Yahoo Finance
Here's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Study finds Cologuard Plus efficient for colorectal cancer screening By Investing.com - Investing.com Nigeria
Study finds Cologuard Plus efficient for colorectal cancer screening - Investing.com
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies - Yahoo Finance
Real time pattern detection on Exact Sciences Corporation stockWeekly Profit Analysis & Weekly High Momentum Picks - newser.com
Why Exact Sciences Corporation stock is in analyst buy zone2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Will Exact Sciences Corporation see short term momentumTrade Ideas & Fast Moving Market Watchlists - newser.com
How Recent Developments Are Reshaping the Story for Exact Sciences - Yahoo Finance
Will Analyst Upgrades and Earnings Revisions Shift Exact Sciences' (EXAS) Investment Narrative? - simplywall.st
Exact Sciences (EXAS): Evaluating Upside Potential as Analyst Optimism and New Catalysts Drive Attention - simplywall.st
Best data tools to analyze Exact Sciences Corporation stockTrade Risk Summary & Technical Pattern Based Signals - newser.com
Will Exact Sciences Corporation (EXK) stock announce special dividendEarnings Beat & Accurate Entry and Exit Point Alerts - newser.com
How sentiment analysis helps forecast Exact Sciences Corporation2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Using economic indicators to assess Exact Sciences Corporation potentialTrade Risk Assessment & Precise Trade Entry Recommendations - newser.com
Will Exact Sciences Corporation stock deliver consistent dividendsWeekly Gains Report & Capital Efficiency Focused Strategies - newser.com
Is Exact Sciences Corporation forming a reversal patternJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
EXAS: Barclays Raises Price Target to $65.00 Amid Overweight Rat - GuruFocus
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock - Yahoo Finance
Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Published on: 2025-10-01 06:45:18 - newser.com
Benchmark raises Exact Sciences stock price target to $60 on cancer test launch - Investing.com
Archford Capital Strategies LLC Acquires New Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exact Sciences Corp Stock (EXAS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Doyle James Edward | Director |
Oct 09 '25 |
Sale |
60.00 |
2,000 |
120,000 |
57,962 |
1.61%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):